FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1929-1930 May 5, 2005 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: The addition of chemoradiation therapy to cytoreductive surgery for malignant pleural mesothelioma can improve survival.¹ Postradiation sarcoma has been reported in patients with breast, cervical, and head and neck cancers.² Here, we describe a 56-year-old woman in whom unclassified spindle-cell sarcoma was diagnosed 14 years after pleurectomy and chemoradiation therapy for malignant pleural mesothelioma.

The patient originally underwent pleurectomy and adjuvant chemoradiation therapy for primary malignant pleural mesothelioma, receiving four cycles of chemotherapy and 45 Gy of radiation to the left chest. She presented 14 years later with intermittent dyspnea and chest pain. Computed tomography of the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.